Biomolecular Life Holdings Discloses $400K Related-Party Convertible Note and Warrant
Summary
Biomolecular Life Holdings disclosed a $400,000 related-party convertible note and warrant issued to its controlling trust on October 7, 2026. The financing carries conversion and exercise prices well above the current stock price, was not negotiated at arm's length, and the company has no committed source of repayment.
Key Events · Financing and Capital Events · BIOM
-
$400K Related-Party Convertible Note
On October 7, 2026, the company issued a $400,000 convertible promissory note to The David and Jessika Contreras Living Trust, bearing 6% interest and maturing October 6, 2027. The note converts at $1.00 per share, above the current $0.83 stock price.
-
Five-Year Warrant at $3.00 Strike
The company also issued a five-year warrant to purchase 400,000 shares at $3.00 per share. Full conversion and exercise would require issuing 800,000 shares, approximately 1.5% of the 51,161,595 shares outstanding.
-
No Arm's-Length Negotiation
Jessika Wiesner, the sole director and officer, executed the note and warrant on behalf of both the company and the trust. No independent director, committee, or financial advisor reviewed the transaction, and no fairness determination was obtained.
-
Going Concern and Demand Debt
The filing reiterates substantial doubt about the company's ability to continue as a going concern. As of June 30, 2026, the company had $1,537,932 in demand-repayable indebtedness and no cash on hand before the $400,000 financing.
Analysis · BIOM · Life Sciences
The company's controlling trust provided $400,000 in financing on October 7, 2026, through a convertible note and warrant. The note converts at $1.00 per share and the warrant is exercisable at $3.00 per share, both well above the current $0.83 stock price. The terms were not negotiated at arm's length — the sole officer and director executed the documents on behalf of both the company and the trust. The company has no committed source of funds to repay the note at maturity in October 2027, and the trust controls 99.99% of voting power, giving it unilateral authority over any default, acceleration, or conversion decision. This financing is the company's only source of liquidity since the June 2026 change of control, and the filing reiterates substantial doubt about the company's ability to continue as a going concern.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 40.4% of the 1069 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIOM was trading at $0.83 on OTC in the Life Sciences sector, with a market capitalization of approximately $875.5K. The 52-week trading range was $0.02 to $2.25. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.